Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03917420 · ClinicalTrials.gov registry record · Phase 1
Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03917420 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 10 participants.
The verdict
NCT03917420, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Purpose: To Assess the impact of high and low in vivo estradiol exposure on PrEP (Pre-exposure prophylaxis) nucleotide concentrations in different cellular populations of the lower GI (gastrointestinal) tract and to quantify the relationship between estradiol, progesterone, and testosterone on PrEP nucleotide concentrations in rectal and peripheral blood mononuclear cells. As well as the relationship between estradiol, progesterone, and testosterone on PrEP concentrations in plasma. Participants: Healthy, cisgender female, volunteers, aged 18-49 inclusive on the date of screening with an intact gastrointestinal system and regular menstrual cycle. Procedures (methods): Participants will take a single daily dose of study drug for five days before each sampling visit. The visits will be scheduled during the early follicular phase of the menstrual cycle (approximately days 2-5 after the first day of menses, Visit 1) when estradiol is predicted to be the lowest and the late follicular phase (approximately days 12-15 after the first day of menses, Visit 2) when estradiol is predicted to be highest. Samples of blood, rectal cells, and rectal tissue will be collected at both Visits 1 and 2. All participants will complete a follow-up safety visit within 14 days of completing study sampling.
Interventions
- DRUG Tenofovir 300Mg Oral Tablet
- DRUG Emtricitabine 200 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2019-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03917420
The ClinicalTrials.gov registry entry for NCT03917420 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tenofovir 300Mg Oral Tablet is the first listed.
NCT03917420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03917420 about?
NCT03917420 is a clinical study titled "Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract". Purpose: To Assess the impact of high and low in vivo estradiol exposure on PrEP (Pre-exposure prophylaxis) nucleotide concentrations in different cellular populations of the lower GI (gastrointestinal) tract and to quantify the relationship between estradiol, progesterone, and testosterone on PrEP ...
What is the current status of trial NCT03917420?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-03-26. Estimated completion is 2019-09-04.
What interventions are being tested in trial NCT03917420?
The interventions under investigation include: Tenofovir 300Mg Oral Tablet (DRUG), Emtricitabine 200 MG (DRUG).
Who is sponsoring clinical trial NCT03917420?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.